08:00 , Dec 12, 2011 |  BC Week In Review  |  Company News

Axis-Shield, Gold Standard Diagnostics sales and marketing update

Gold Standard launched Axis-Shield's Anti-CCP2 assay in the U.S for the early diagnosis of rheumatoid arthritis (RA). The assay, which has 510(k) clearance, is an ELISA that detects autoantibodies against second generation cyclic citrullinated peptides...
07:00 , Oct 31, 2011 |  BC Week In Review  |  Company News

Alere, Axis-Shield deal

Alere said that its revised offer for fellow diagnostics company Axis-Shield is unconditional now that Alere holds 25.2 million, or 50.4%, of Axis-Shield's outstanding shares. The offer was to expire on Oct. 24 but will...
07:00 , Oct 31, 2011 |  BC Week In Review  |  Company News

Axis-Shield, Siemens deal

Axis-Shield granted Siemens' Siemens Healthcare Diagnostics unit a non-exclusive, worldwide license to develop Axis-Shield's anti-CGP test for early detection of rheumatoid arthritis (RA) to run on Siemens' automated Siemens ADVIA Centaur Immunoassay System. Axis-Shield's ELISA...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Company News

Alere, Axis-Shield deal

Axis-Shield recommended that shareholders accept a takeover bid from fellow diagnostics company Alere. Alere, which said at the end of September that it owned 29.9% of Axis-Shield, increased its offer to 470p per share from...
00:46 , Oct 7, 2011 |  BC Extra  |  Company News

Axis-Shield recommends Alere's higher offer

Axis-Shield plc (LSE:ASD; OSE:ASD) recommended that shareholders accept a takeover bid from fellow diagnostics company Alere Inc. (NYSE:ALR). Alere, which already owns 30% of Axis-Shield, increased its offer to 470p per share from 460p per...
07:00 , Oct 3, 2011 |  BC Week In Review  |  Company News

Alere, Axis-Shield deal

Axis-Shield's board said it was "disappointed" that the "firm rebuttal" from shareholders against Alere's "wholly inadequate offer" has not been noticed by the fellow diagnostics company. Alere reiterated its unsolicited tender offer to acquire Axis-Shield...
07:00 , Oct 3, 2011 |  BioCentury  |  Finance

Cost averaging down

Even the best fundamentals may not be able to overcome the negative effects of the broader economy on the stock market this quarter. As a result, specialists have little hope of major gains and instead...
07:00 , Oct 3, 2011 |  BioCentury  |  Finance

Few Cinderellas this time

Big caps suffered the least in a very ugly quarter. But that's not saying much: biotechs with market caps of more than $5 billion were still down 10% as a group in 3Q, while other...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Company News

Alere, Axis-Shield deal

Alere extended its unsolicited tender offer to acquire fellow diagnostics company Axis-Shield for 460p per share in cash to Oct. 10. At Sept. 15, Alere said 498,754 shares had been tendered. The tender, combined with...
07:00 , Sep 12, 2011 |  BC Week In Review  |  Company News

Alere, Axis-Shield deal

Alere extended to 1 pm GMT on Sept. 15 the deadline for its unsolicited tender offer to acquire fellow diagnostic company Axis-Shield for 460p per share in cash. At Sept. 1, Alere said 471,116 shares...